The annual meeting of the American Society of Clinical Oncology (ASCO) in 2024 focuses on new four-part drug combinations for patients with multiple myeloma and the potential impact on treatment. Quadruple therapy involves adding a monoclonal antibody drug to standard treatments, resulting in deeper responses and longer survival. Studies test the effectiveness of these combinations and the possibility of reducing the need for bone marrow transplants. Access to newer drugs and treatment traditions can influence patient care. Future developments include precision medicine, improved MRD detection, and the possibility of using CAR T-cell therapy instead of transplants. Collaboration among experts is key to advancing patient care.
Source link
Evolving treatment paradigms in multiple myeloma could improve patient outcomes
